Exodus Point Capital Management, LP Global Blood Therapeutics, Inc. Transaction History

Exodus Point Capital Management, LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$32.4 - $68.18 $857,692 - $1.8 Million	-26,472 Closed	0 $0
Q2 2022 Aug 19, 2022	BUY	$22.3 - $37.39 $590,325 - $989,788	26,472 New	26,472 $846,000
Q4 2021 Feb 11, 2022	SELL	$24.9 - $40.26 $687,812 - $1.11 Million	-27,623 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$25.48 - $37.34 $703,834 - $1.03 Million	27,623 New	27,623 $704,000
Q2 2021 Aug 16, 2021	SELL	$32.46 - $43.42 $375,594 - $502,412	-11,571 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$38.94 - $50.85 $450,574 - $588,385	11,571 New	11,571 $472,000
Q4 2020 Feb 16, 2021	SELL	$37.65 - $63.77 $2.47 Million - $4.18 Million	-65,587 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$52.76 - $74.49 $1.92 Million - $2.71 Million	-36,405 Reduced 35.69%	65,587 $3.62 Million
Q2 2020 Aug 14, 2020	BUY	$48.73 - $81.82 $4.72 Million - $7.93 Million	96,939 Added 1918.44%	101,992 $6.44 Million
Q1 2020 May 15, 2020	BUY	$41.72 - $87.2 $210,811 - $440,621	5,053 New	5,053 $258,000
Q3 2019 Nov 14, 2019	SELL	$45.35 - $57.91 $202,850 - $259,031	-4,473 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$52.6 - $63.29 $235,279 - $283,096	4,473 New	4,473 $235,000

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.